Document ID: chunk:federal_register_of_legislation:F2025L00149:front:0:p5
Version: federal_register_of_legislation:F2025L00149
Segment Type: other
Provision Reference: 
Character Range: 11404–15822

one of the following vasculitides at the time of clinical onset or clinical worsening:
         1.           antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis;
         2.           Behcet disease;
         3.           eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome);
         4.           giant cell (temporal) arteritis;
         5.           granulomatosis with polyangiitis (Wegener granulomatosis);
         6.            IgA vasculitis (Henoch-Schönlein purpura);
         7.           microscopic polyangiitis;
         8.           mucocutaneous lymph node syndrome (Kawasaki disease);
         9.             non-specific autoimmune vasculitis;
        10.             polyarteritis nodosa;
        11.           Takayasu arteritis;
 5.       having thromboangiitis obliterans (Buerger disease) before the clinical onset of myocardial infarction;
 6.       having one of the following systemic inflammatory rheumatological diseases at the time of clinical onset or clinical worsening:
         1.           ankylosing spondylitis;
         2.           dermatomyositis;
         3.           inflammatory bowel disease;
         4.           polymyositis;
         5.           psoriasis;
         6.            psoriatic arthritis;
         7.           rheumatoid arthritis;
         8.           Sjögren syndrome;
         9.             systemic lupus erythematosus;
        10.             systemic sclerosis;
 7.       having a hypercoagulable state that results in thrombosis of a coronary artery at the time of clinical onset or clinical worsening;
Note: Some examples of hypercoagulable state include acquired antithrombin III deficiency, disseminated intravascular coagulation, secondary thrombocytosis and acute myeloid leukaemia.
 1.       having one of following clinically significant disorders of mental health for at least the 5 years before clinical onset or clinical worsening;
         1.           adjustment disorder;
         2.           agoraphobia;
         3.           anxiety disorder;
         4.           depressive disorder;
         5.           panic disorder;
         6.            posttraumatic stress disorder;
         7.           schizophrenia; or
         8.           social anxiety disorder.
Note: clinically significant disorder of mental health is defined in the Schedule 1 – Dictionary.
 1.       taking combined estrogen-progestogen contraception within the 4 weeks before clinical onset or clinical worsening of myocardial infarction or unstable angina;
 2.       taking any of the following medications, within the 24 hours before clinical onset or clinical worsening:
         1.           alemtuzumab;
         2.           aromatase inhibitors;
         3.           bevacizumab;
         4.           capecitabine;
         5.           dextroamphetamine;
         6.            docetaxel;
         7.           ephedrine;
         8.           ergotamine;
         9.             fluorouracil;
        10.             methylphenidate;
        11.           paclitaxel;
        12.             phentermine;
        13.         pseudoephedrine;
        14.           the kinase inhibitors, axitinib, cabozantinib, dasatinib, erlotinib, lenvatinib, midostaurin, nilotinib, nintedanib, pazopanib, ponatinib, regorafenib, sorafenib; or
        15.           triptans, including sumatriptan.
 3.       being treated with antipsychotic agents or macrolide antibiotics within the 24 hours before the clinical onset or clinical worsening of myocardial infarction;
 4.       taking a non-topical, non-steroidal, anti-inflammatory drug, excluding aspirin and paracetamol, for a continuous period of at least 3 days before clinical onset or clinical worsening, where the last dose of the drug was taken within the 7 days before clinical onset or clinical worsening;
Note: non-steroidal, anti-inflammatory drug is defined in the Schedule 1 - Dictionary.
 1.       having bilateral orchidectomy (orchiectomy) before clinical onset or clinical worsening
 2.       taking one of the following anti-androgen medications for at least the 7 days before clinical onset or clinical worsening:
         1.           abiraterone;
         2.           androgen receptor blockers, including apalutamide, bicalutamide, darolutamide, enzalutamide, and cyproterone acetate; or
         3.           gonadotrophin releasing hormone agonists,